Iterum Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
2024年8月8日 - 5:30AM
Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a
clinical-stage pharmaceutical company focused on developing next
generation oral and IV antibiotics to treat infections caused by
multi-drug resistant pathogens in both community and hospital
settings, today announced that the Company will release its
second quarter 2024 financial results before the open of
the U.S. financial markets on Wednesday, August 14,
2024. Management will host a conference call at 8:30 a.m.
ET that day to discuss the Company’s financial results and
provide an update on its business.
To access the call please dial 833-470-1428
(domestic) or 404-975-4839 (international) and refer to Access Code
775539. To pre-register for this call, please go to the following
link: . The audio webcast can be accessed under “Financials &
Filings” in the Investors section of the Company’s website at
www.iterumtx.com following the call.
About Iterum Therapeutics
plc
Iterum Therapeutics plc is a clinical-stage
pharmaceutical company dedicated to developing differentiated
anti-infectives aimed at combatting the global crisis of multi-drug
resistant pathogens to significantly improve the lives of people
affected by serious and life-threatening diseases around the world.
Iterum Therapeutics is advancing the development of its first
compound, sulopenem, a novel penem anti-infective compound, with an
oral formulation and IV formulation. Sulopenem has demonstrated
potent in vitro activity against a wide variety of gram-negative,
gram-positive and anaerobic bacteria resistant to other
antibiotics. Iterum Therapeutics has submitted an NDA for oral
sulopenem for the treatment of uncomplicated urinary tract
infections in adult women, which has been accepted for review by
the U.S. Food and Drug Administration and has received Qualified
Infectious Disease Product (QIDP) and Fast Track designations for
its oral and IV formulations of sulopenem in seven indications. For
more information, please visit http://iterumtx.com.
Investor Contact:Judy
MatthewsChief Financial Officer
312-778-6073IR@iterumtx.com
Iterum Therapeutics (NASDAQ:ITRM)
過去 株価チャート
から 7 2024 まで 8 2024
Iterum Therapeutics (NASDAQ:ITRM)
過去 株価チャート
から 8 2023 まで 8 2024